Viramal is a Specialty Pharmaceutical Company developing a portfolio of therapies in the fields of male & female sexual health focussing on the utilisation and application of sex steroid hormones. Viramal’s patent protected technology platform facilitates superior drug delivery both transdermally and to sensitive female reproductive areas with an outstanding safety profile. Similar to cosmetic creams, Viramal’s products have excellent patient acceptability, and unlike competitors does not require alcohol for API solubility or absorption enhancement. All of the Company’s products benefit from the avoidance of the First Hepatic Pass, and the safety/ metabolite concerns that result other marketed products, particularly in Menopausal Hormone Therapy. The portfolio is made up of products in the following area’s: 1. Sex Steroid Hormone Deficiencies * Testosterone Replacement for Men * Menopausal Hormone Therapy 2. Reproductive & Fertility * Fertility Support * Endometriosis & Fibromyomas – treating symptoms and enabling fertility within women of reproductive age 3. Contraception & General Sexual Health * Safer and more patient-acceptable daily & emergency contraceptives * Gynaecological health Viramal’s lead product, TestoCream, is expected to be filed for a New Drug Application to the FDA in the US in 2017/18. TestoCream is a testosterone replacement therapy, similar to a cosmetic cream, applied to the skin. Unlike competing products, TestoCream is neither messy nor watery, requiring a smaller area for application, and it is also quick drying. Testosterone is only soluble in alcohol, with competing products having an alcohol content of around 70% or more. TestoCream offers a far safer alternative, having less than 3.5% alcohol, reducing the risk of skin irritation.